Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

Table 4 Available and ongoing clinical results about drugs targeting mainly stroma in pancreatic adenocarcinoma

Combination	Target (s)	Setting	Clinical trial identifier1	Expected end of accrual
Demcizumab	Cancer stem cells by DLL4 inhibition	Phase Ib, plus GEM +/- Nab-P	NCT01189929	Concluded. presented at ASCO 2014: Increase in ORR, cardiovascular toxicity
(Gracian 2014)
Ruxolitinib (Hurwitz 2014)	Inflammation by JAK/STAT inhibition	Phase II, 2nd line, plus CAPE	NCT01423604	Concluded. presented at ASCO 2014: Benefit in patients with elevated CRP
PEGPH20	HA by Pegylated-hyaluronidase	Phase II, 1st line, plus GEM	NCT01453153	Concluded. presented at ASCO 2013: ORR 33%, especially in patients with high HA expression
(Hingorani 2013)S
‘’	‘’	Phase II, plus GEM + Nab-P	NCT01839487	July 16

CAPE: Capecitabine; CRP: C-reactive protein; GEM: Gemcitabine; HA: Hyaluronic acid; ORR: Objective response rate; DLL4: Delta like ligand 4; ASCO: American society of clinical oncology; JAK/STAT: Janus kinase/signal transducer and activator of transcription; Nab-P: Nab-paclitaxel.

¹Data Available from: URL: http// http://www.clinicaltrials.gov (last access 2015 May 24).